The association between body mass index and immunohistochemical subtypes in breast cancer

Şahin, Süleyman; Erdem, Gökmen Umut; Karataş, Fatih; Aytekin, Aydın; Sever, Ali; Özışık, Yavuz; Altundağ, Kadri̇

doi:10.1016/j.breast.2016.09.019

Cited by 32 publications

(33 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…molec-ular apocrine, claudin-low and different subtypes of triple negative tumors. Nevertheless, in a recent study, which analyzed 3767 breast cancer patients, it has been observed that overweight premenopausal patients had more HER2-enriched subtype compared to normal weight patients [154]. Furthermore, in postmenopausal patients, HER2/luminal-like subtype was found to be significantly associated with overweight BMI.…”

Section: Clinical Studies On Breast Cancer and Her2 With Reference Tomentioning

confidence: 99%

Tumor-linked HER2 expression: association with obesity and lipid-related microenvironment

Ray

2017

Hormone Molecular Biology and Clinical Investigation

View full text Add to dashboard Cite

Abstract:Obesity is associated with the risk of several health disorders including certain cancers. Among obesity-related cancers, postmenopausal breast carcinoma is a well-studied one. Apart from an increase in certain types of lipids in obesity, excess adipose tissue releases many hormone-like cytokines/adipokines, which are usually pro-inflammatory in nature. Leptin is one of such adipokines and significantly linked with the intracellular signaling pathways of other growth factors such as insulin-like growth factor-1 (IGF-1), vascular endothelial growth factor (VEGF), human epidermal growth factor receptor 2 (HER2). In general, HER2 is overexpressed in roughly 30% of breast carcinomas; its presence indicates aggressive tumor behavior. Conversely, HER2 has certain effects in normal conditions such as differentiation of preadipocytes, cardiovascular health and vitamin D metabolism. HER2 has no known endogenous ligand, but it may form dimers with other three members of the epidermal growth factor receptor (EGFR) family and can activate downstream signaling pathways. Furthermore, HER2 is intimately connected with several enzymes, e.g. fatty acid synthase (FASN), phosphatidylinositol 3-kinase (PI3K), AKT and mechanistic target of rapamycin (mTOR), all of which play significant regulatory roles in lipogenic pathways or lipid metabolism. In obesity-related carcinogenesis, characteristics like insulin resistance and elevated IGF-1 are commonly observed. Both IGF-1 and leptin can modulate EGFR and HER2 signaling pathways. Although clinical studies have shown mixed results, the behavior of HER2+ tumor cells including HER2 levels can be altered by several factors such as obesity, leptin and fatty acids. A precise knowledge is useful in new therapeutic approaches against HER+ tumors.

show abstract

Section: Clinical Studies On Breast Cancer and Her2 With Reference Tomentioning

confidence: 99%

Tumor-linked HER2 expression: association with obesity and lipid-related microenvironment

Ray

2017

Hormone Molecular Biology and Clinical Investigation

View full text Add to dashboard Cite

show abstract

“…The majority of breast tumors (>70%) express the estrogen receptor (ER) and are diagnosed after menopause. Women with obesity are more likely than their lean counterparts to face a poor breast cancer prognosis both before and after menopause (1)(2)(3). It is estimated that each 5-unit increase in BMI translates to ~8% greater risk of cancer recurrence or death (4).…”

Section: Introductionmentioning

confidence: 99%

FGFR1 underlies obesity-associated progression of estrogen receptor–positive breast cancer after estrogen deprivation

Wellberg¹,

Kabos²,

Gillen³

et al. 2018

JCI Insight

View full text Add to dashboard Cite

“…In a meta-analysis, the clinical importance of obesity on breast cancer risk was not seen [ 17 ]. There are studies showing a positive correlation of BMI with tumour size, stage and grade of the tumour [ 18 – 22 ]. BMI and its relation to the breast cancer subtype have also been studied, but with conflicting data.…”

Section: Discussionmentioning

confidence: 99%

“…BMI and its relation to the breast cancer subtype have also been studied, but with conflicting data. In a large retrospective analysis of 3,767 breast cancer patients, authors concluded that TNBC subtype had a significant association with premenopausal obesity [ 22 ]. Similar conclusions were made by other studies as well that analysed the BMI and its association with breast cancer subtype [ 23 – 25 ].…”

Section: Discussionmentioning

confidence: 99%

Correlation of BMI with breast cancer subtype and tumour size

Babu

Anand

Lakshmaiah

et al. 2018

ecancer

View full text Add to dashboard Cite

BackgroundBreast cancer is a heterogeneous disease which is divided broadly into luminal, HER2 and basal type based on molecular profiling. Increased body mass index (BMI) has been associated with the risk of developing breast cancer but the association based on molecular subtype remains conflicting.MethodsThis was an observational study carried out over a period of 2 years. Nonmetastatic breast cancer patients were evaluated for the tumour subtype based on surrogate markers (ER, PR and HER2). The BMI of these patients was correlated with the tumour subtype and size.ResultsWe studied 476 patients with breast cancer with the median age of 46 years (range, 25–86) and 58% were premenopausal. The mean BMI of the cohort was 24.1, which was significantly higher in postmenopausal women (24.9 versus 23.6, p < 0.05). Overall, only 10% of patients were obese. The mean BMI in the luminal, HER2 and TNBC subtypes was 24.7, 22.4 and 23.9, respectively (p < 0.01). Also, the mean tumour size in luminal, HER2 and TNBC subtype was 4.02, 3.80 and 4.27 cm, respectively (p = 0.158).ConclusionThe average BMI was higher in patients with luminal subtype followed by TNBC and lowest for HER2 at the time of diagnosis. The mean tumour size was numerically higher for TNBC and lowest for HER2 subtype although the difference was not statistically significant. Larger studies may provide clarity of association between the BMI and tumour subtype.

show abstract

The association between body mass index and immunohistochemical subtypes in breast cancer

Cited by 32 publications

References 34 publications

Tumor-linked HER2 expression: association with obesity and lipid-related microenvironment

Tumor-linked HER2 expression: association with obesity and lipid-related microenvironment

FGFR1 underlies obesity-associated progression of estrogen receptor–positive breast cancer after estrogen deprivation

Correlation of BMI with breast cancer subtype and tumour size

Contact Info

Product

Resources

About